C2N Diagnostics
Biotechnology Research • St. Louis, Missouri, United States
C₂N Diagnostics’ vision is to bring Clarity Through Innovation™. It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. Diagnostic efforts revolve around bringing accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring. Its lead commercial product, the PrecivityAD™ blood test, is a mass spectrometry-based test performed in C₂N’s CLIA-certified lab that measures in blood multiple analytes including Aβ42, Aβ40, and apolipoprotein E isoforms. While the test by itself cannot diagnose Alzheimer’s disease —…
Reported headcount
112
Headcount reported in the resolved company record. It is independent of the number of profiles indexed by Super Carl.
Company record. Source date unavailable.
Observed active job postings
25
Active postings in the available job data. Postings may be duplicated or stale and are not a verified count of vacancies or hires.
Indexed job postings. Source date unavailable.
Reported annual revenue estimate
$7.5M
Annual revenue from the resolved company record; estimates may differ from filed accounts.
Company record. Source date unavailable. Estimate.
Reported total funding
$96.7M
Reported cumulative funding in the available company record; missing value does not mean no funding.
Company record. Source date unavailable.
Reported latest funding round
0M
Reported amount of the latest funding round available in the company record.
Company record. Source date unavailable.
Calculated as of 2026-09-21. Source records may be older.